Twelve months after starting, 48% of one Danish practice’s 206 patients were still taking semaglutide. Among those the maintenance dose split three ways: 40% at 1.0 mg a week or less, 30% at 1.7 mg and 30% at 2.4 mg. Titration was slower and maintenance lower than the approved labeling describes, which is a gap between what a product is licensed to do and what people actually settle into.
The guide to restarting a GLP-1 after a break explains why the previous dose is worth discussing with your prescriber. A woman in one case report restarted at 2.4 mg after a five-week break [2]. A day later she needed hospital care for severe nausea, vomiting, diarrhea and electrolyte abnormalities. A single case cannot establish how often this happens.
The long-term safety guide summarizes adverse events in randomized trials. When comparing this Danish practice with other studies of treatment continuation, check how each study defines a pause or discontinuation. A gap between refills can be counted differently from a documented decision to stop treatment.
What was observed
Researchers followed 206 people prescribed semaglutide for weight management in a single general practice [1]. The full cohort had a mean age of 48. Mean starting weight was 105 kg among the 116 people included in the primary weight analysis.
At twelve months, 78 people (38%) had permanently discontinued and 30 (15%) were on a temporary pause, leaving 98 (48%) actively taking it at that point. Of those 98, about 40% were taking 1.0 mg a week or less, 30% were taking 1.7 mg, and 30% were taking 2.4 mg. Only 31% of the original group had continued through the year without a pause [1].
The result, with its clause attached
The primary weight analysis included 116 patients with baseline and follow-up measurements who had not permanently discontinued treatment. Temporary pauses were allowed. At the 12-month follow-up, with a four-month window on either side, mean weight change was −13.6% (95% CI −15.0 to −12.2) [1].
The practice often raised doses more slowly and used lower ongoing doses than the labeling described. Because this was an observational study, it cannot establish how different assigned doses would compare.
What it means for a price
Compare the price at your prescribed dose and the cost if your prescriber changes it. A flat rate makes the dose-related cost more predictable. A dose-based plan may cost less at a lower dose, depending on the prices and fees for both plans. Among sellers with a comparable price in our dataset, 68 sellers state a flat figure and 18 state that the price climbs, out of 183. The remainder — 97 of them, 53% — say nothing at all, and silence is the one answer a buyer cannot plan against.
At the median billed price of $186 a month, a year of injected semaglutide would cost $2,232 if the price stays the same. The monthly GLP-1 cost guide explains which fees are included in that median. Price verification dates vary by provider.
Before paying for several months upfront, use the GLP-1 prepayment guide to compare the discount with the refund terms. Ask the seller what happens to your payment if your prescriber changes your treatment.